BR112015005583A2 - método para o diagnóstico de um fenótipo molecular de um paciente que sofre de uma doença associada à inflamação crônica - Google Patents
método para o diagnóstico de um fenótipo molecular de um paciente que sofre de uma doença associada à inflamação crônicaInfo
- Publication number
- BR112015005583A2 BR112015005583A2 BR112015005583A BR112015005583A BR112015005583A2 BR 112015005583 A2 BR112015005583 A2 BR 112015005583A2 BR 112015005583 A BR112015005583 A BR 112015005583A BR 112015005583 A BR112015005583 A BR 112015005583A BR 112015005583 A2 BR112015005583 A2 BR 112015005583A2
- Authority
- BR
- Brazil
- Prior art keywords
- chronic inflammation
- diagnosing
- molecular phenotype
- patient suffering
- disease associated
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Abstract
resumo da patente de invenção para: método para o diagnóstico de um fenótipo molecular de um paciente que sofre de uma doença associada à inflamação crônica. a inflamação crônica constitui um problema médico crescente de elevada relevância socioeconômica. a presente invenção diz respeito a um método e a um kit destinados ao diagnóstico de um fenótipo molecular de um paciente que sofre de uma doença acompanhada de inflamação crônica, e a um medicamento para o tratamento de tal paciente. para tal, procede-se a medição da expressão dos genes gata-3 e/ou tbet num isolado biológico, utilizando-se em associação a um fenótipo molecular da doença.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12184500.2A EP2708898A1 (de) | 2012-09-14 | 2012-09-14 | Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten |
PCT/EP2013/068317 WO2014040891A2 (de) | 2012-09-14 | 2013-09-04 | Verfahren zur diagnose eines molekularen phänotyps eines an einer mit chronischen entzündungen einhergehenden erkrankung leidenden patienten |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015005583A2 true BR112015005583A2 (pt) | 2017-08-08 |
Family
ID=46963488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015005583A BR112015005583A2 (pt) | 2012-09-14 | 2013-09-04 | método para o diagnóstico de um fenótipo molecular de um paciente que sofre de uma doença associada à inflamação crônica |
Country Status (9)
Country | Link |
---|---|
US (2) | US9791454B2 (pt) |
EP (1) | EP2708898A1 (pt) |
JP (2) | JP6401163B2 (pt) |
KR (1) | KR102157768B1 (pt) |
AU (2) | AU2013314510A1 (pt) |
BR (1) | BR112015005583A2 (pt) |
CA (2) | CA2888860C (pt) |
RU (1) | RU2672595C2 (pt) |
WO (1) | WO2014040891A2 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3093022B1 (en) * | 2015-05-15 | 2019-08-07 | Sterna Biologicals GmbH & Co. KG | Gata-3 inhibitors for use in the treatment of th2-driven asthma |
US10905710B2 (en) | 2016-05-24 | 2021-02-02 | Emory University | Particles with RNA cleaving nucleobase polymers and uses for managing inflammatory disorders |
EP3501607A1 (de) * | 2017-12-22 | 2019-06-26 | Sterna Biologicals GmbH & Co. KG | Zusammensetzung zur behandlung eines an einer mit chronischen entzündungen einhergehenden atemwegserkrankung leidenden patienten sowie herstellungsverfahren und verwendung der zusammensetzung |
EP3514235B8 (de) * | 2018-01-18 | 2024-02-14 | Sterna Biologicals GmbH | Zusammensetzung zur behandlung eines an colitis ulcerosa leidenden patienten sowie verwendung der zusammensetzung als arzneimittel |
EP3603617A1 (de) * | 2018-07-30 | 2020-02-05 | Sterna Biologicals GmbH & Co. KG | Aerosolerzeugungseinrichtung zur inhalativen verabreichung einer antisense-molekül-haltigen zusammensetzung |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10346487A1 (de) * | 2003-10-02 | 2005-05-12 | Transmit Technologietransfer | Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels |
US8853264B2 (en) * | 2005-01-07 | 2014-10-07 | Newtree Industry Co., Ltd. | Use of lignan compounds for treating or preventing inflammatory disease |
WO2008021532A2 (en) | 2006-08-17 | 2008-02-21 | University Of Chicago | Treatment of inflammatory diseases |
EP2227232A1 (en) * | 2007-12-07 | 2010-09-15 | Fibrogen, Inc. | Methods for inhibiting t helper cell differentiation |
CN112481367A (zh) | 2008-03-31 | 2021-03-12 | 健泰科生物技术公司 | 用于治疗和诊断哮喘的组合物和方法 |
JP2012520685A (ja) * | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害 |
EP2460880B1 (en) * | 2009-07-29 | 2014-11-19 | Sysmex Corporation | Marker and reagent for detection of human il-17-producing helper t cells, and method for detection of human il-17-producing helper t cells |
-
2012
- 2012-09-14 EP EP12184500.2A patent/EP2708898A1/de not_active Withdrawn
-
2013
- 2013-09-04 RU RU2015112894A patent/RU2672595C2/ru active
- 2013-09-04 WO PCT/EP2013/068317 patent/WO2014040891A2/de active Application Filing
- 2013-09-04 AU AU2013314510A patent/AU2013314510A1/en not_active Abandoned
- 2013-09-04 CA CA2888860A patent/CA2888860C/en active Active
- 2013-09-04 KR KR1020157009484A patent/KR102157768B1/ko active IP Right Grant
- 2013-09-04 CA CA3199111A patent/CA3199111A1/en active Pending
- 2013-09-04 JP JP2015531519A patent/JP6401163B2/ja active Active
- 2013-09-04 US US14/428,043 patent/US9791454B2/en active Active
- 2013-09-04 BR BR112015005583A patent/BR112015005583A2/pt not_active Application Discontinuation
-
2017
- 2017-10-12 US US15/782,595 patent/US10591489B2/en active Active
-
2018
- 2018-09-06 JP JP2018167068A patent/JP6662969B2/ja active Active
-
2019
- 2019-06-12 AU AU2019204108A patent/AU2019204108B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20180031571A1 (en) | 2018-02-01 |
AU2019204108A1 (en) | 2019-07-04 |
JP2015531482A (ja) | 2015-11-02 |
CA2888860C (en) | 2023-07-18 |
US9791454B2 (en) | 2017-10-17 |
JP2019007977A (ja) | 2019-01-17 |
AU2019204108B2 (en) | 2021-11-25 |
EP2708898A1 (de) | 2014-03-19 |
KR20150064084A (ko) | 2015-06-10 |
JP6401163B2 (ja) | 2018-10-03 |
US10591489B2 (en) | 2020-03-17 |
JP6662969B2 (ja) | 2020-03-11 |
WO2014040891A2 (de) | 2014-03-20 |
RU2672595C2 (ru) | 2018-11-16 |
WO2014040891A3 (de) | 2014-05-30 |
RU2015112894A (ru) | 2016-11-10 |
CA2888860A1 (en) | 2014-03-20 |
CA3199111A1 (en) | 2014-03-20 |
AU2013314510A1 (en) | 2015-04-09 |
KR102157768B1 (ko) | 2020-09-21 |
US20150260728A1 (en) | 2015-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
BR112013010015A2 (pt) | aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos | |
AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
BR112015005583A2 (pt) | método para o diagnóstico de um fenótipo molecular de um paciente que sofre de uma doença associada à inflamação crônica | |
SG195191A1 (en) | Methods and compositions of predicting activity of retinoid x receptor modulator | |
BR112013028808A2 (pt) | métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada | |
BR112015015131A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto | |
BR112014008731A2 (pt) | tratamento de esclerose múltipla com combinação de laquinimode e fingolimode | |
BR112014011896A2 (pt) | agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr) | |
BR112014009415A2 (pt) | inibidores de arginase e suas aplicações terapêuticas | |
BR112013017314A2 (pt) | composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos | |
BR112014024219A8 (pt) | Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit | |
MX2018004170A (es) | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. | |
BR112018005114A2 (pt) | um novo polipeptídeo de endolisina | |
BR112017004056A2 (pt) | composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo | |
MX2019002377A (es) | Composicion y metodos para la prediccion de la actividad de la enzastaurina. | |
EA201490883A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛА К α-СИНУКЛЕИНУ ДЛЯ ДИАГНОСТИКИ ПОВЫШЕННОГО УРОВНЯ α-СИНУКЛЕИНА В МОЗГЕ | |
BR112017025998A2 (pt) | inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit | |
BR112017025995A2 (pt) | inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal | |
BR112015000808A2 (pt) | regime de dosagem para inibidores de janus quinase (jak) | |
CR20140473A (es) | Compuestos de pirazol como inhibidores de sglt1 | |
BR112016028446A2 (pt) | inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5 | |
BR112012026224A2 (pt) | métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia | |
PH12014501290A1 (en) | Methods and products to diagnose and treat heatiness | |
BR112015000685A2 (pt) | método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: STERNA BIOLOGICALS GMBH AND CO. KG (DE) |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |